Abstract
In this study, we evaluated low dose intravesical bacillus Calmette-Guerin (BCG) therapy following transurethral resection (TUR) in 80 patients with superficial bladder cancer. The patients were divided into two groups. Of the Connaught BCG strain 81 mg was given to 40 patients in Group 1 and 54 mg to the remainder of 40 patients in Group 2. BCG was introduced once a week for 6 weeks. Tumour recurrence was seen in 6 patients in Group 1 and in 10 patients in Group 2. Recurrence rates per month were 0.71 and 1.49, respectively. There was no significant difference in complication rates.
These data suggest that while the standard dose (81 mg) intravesical therapy of BCG is more effective than the low dose, there was no significant difference in side effects between the two groups.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Herr, H. W.: An overview of intravesical therapy for superficial bladder tumors.J. Urol., 16, 1363 (1987).
Soloway, M. S.: Selecting initial therapy for bladder cancer.Cancer, 60, 502 (1987).
Harry, W.: TUR and intravesical therapy of superficial bladder tumor.Urol. Oncol., 18, 525 (1991).
Stenberg, C. N., Scher, H. I.: Advances in the treatment of urothelia tumors.Urol. Clin. N. Am., 14, 373 (1987).
Morales, A.: Intracavitary BCG in treatment of superficial bladder tumor.J. Urol., 116, 180 (1976).
Lamm, D. L.: A randomized prospective comparison of oral versus intracavitary BCG for superficial bladder tumor.J. Urol., 144, 65 (1990).
Brosman, S. A., Lamm, D. L.: Handling and use of intravesical BCG for the management of stage Ta, T1, ca in situ and transitional bladder cancer.J. Urol., 144, 313 (1990).
Haaff, E.: Two courses of intravesical bladder BCG for transitional cell ca.J. Urol., 136, 820 (1986).
Kelley, D. R.: Intravesical BCG therapy for superficial bladder cancer.J. Urol., 136, 48 (1985).
Pagano, F.: Effectiveness of a low dose BCG therapy in superficial cancer.J. Urol., 141, 334 (1989).
Guinuan, P.: BCG in the management of superficial bladder cancer.Urology, 30, 16 (1991).
Lamm, D. L., Griffin, J. G.: Intravesical therapy.Semin. Urol., 10, 39 (1992).
Cockett, A. T. K., Davis, R. S., Cos, L. R., Wheeless, L. L. Jr.: BCG and interleukin-2 for treatment of superficial bladder cancer.J. Urol., 146, 766 (1991).
Pagano, F., Bessi, P.: A low dose BCG regimen in superficial bladder cancer therapy: Is it effective?J. Urol., 146, 32 (1991).
Bast, R. C.: BCG and cancer.N. Engl. J. Med.,2 (1991).
Author information
Authors and Affiliations
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/BF02564870.
Rights and permissions
About this article
Cite this article
Yalçinkaya, F., Kamiş, L., Özteke, O. et al. Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer. International Urology and Nephrology 30, 41–44 (1998). https://doi.org/10.1007/BF02550276
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02550276